137 related articles for article (PubMed ID: 37337439)
21. Severe treatment-resistant acute and recurrent vesicular chronic hand eczema successfully treated with dupilumab.
Halling AS; Zachariae C; Thyssen JP
Contact Dermatitis; 2020 Jul; 83(1):37-38. PubMed ID: 32087035
[No Abstract] [Full Text] [Related]
22. Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experience.
Stingeni L; Bianchi L; Antonelli E; Caroppo ES; Ferrucci SM; Ortoncelli M; Fabbrocini G; Nettis E; Schena D; Napolitano M; Gola M; Bonzano L; Rossi M; Belloni Fortina A; Balato A; Peris K; Foti C; Guarneri F; Romanelli M; Patruno C; Savoia P; Fargnoli MC; Russo F; Errichetti E; Bianchelli T; Bianchi L; Pellacani G; Feliciani C; Offidani A; Corazza M; Micali G; Milanesi N; Malara G; Chiricozzi A; Tramontana M; Hansel K;
J Eur Acad Dermatol Venereol; 2022 Aug; 36(8):1292-1299. PubMed ID: 35412683
[TBL] [Abstract][Full Text] [Related]
23. [Response to treatment with oral alitretinoin in patients with chronic hand eczema that is refractory to treatment with potent topical corticosteroids: experience in 15 patients].
Aguayo-Leiva IR; Urrutia S; Jaén-Olasolo P
Actas Dermosifiliogr; 2011 Oct; 102(8):616-22. PubMed ID: 21354545
[TBL] [Abstract][Full Text] [Related]
24. Dupilumab treatment of nummular dermatitis: A retrospective cohort study.
Choi S; Zhu GA; Lewis MA; Honari G; Chiou AS; Ko J; Chen JK
J Am Acad Dermatol; 2020 May; 82(5):1252-1255. PubMed ID: 31923445
[No Abstract] [Full Text] [Related]
25. Efficacy and safety of oral alitretinoin as treatment for chronic hand eczema in France: a real-life open-label study.
Halioua B; Paul C; Berbis P; Cambazard F; Doutre MS; Joly P; Richard MA; Aubin C; Gruber A; Chosidow O
Eur J Dermatol; 2019 Feb; 29(1):59-66. PubMed ID: 30827949
[TBL] [Abstract][Full Text] [Related]
26. Alitretinoin for severe chronic hand eczema: a NICE single technology appraisal.
Rodgers M; Griffin S; Paulden M; Slack R; Duffy S; Ingram JR; Woolacott N; Sculpher M
Pharmacoeconomics; 2010; 28(5):351-62. PubMed ID: 20131924
[TBL] [Abstract][Full Text] [Related]
27. Alitretinoin: An Update of Real-World Evidence in The Management of Chronic Hand Dermatitis.
Gooderham MJ
Skin Therapy Lett; 2018 Jul; 23(4):1-4. PubMed ID: 30086182
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of alitretinoin depending on the concomitant use of topical corticosteroids in chronic hand eczema patients.
Cheon DU; Kim JE; Ko JY; Ro YS
J Dermatol; 2019 Nov; 46(11):998-1005. PubMed ID: 31535403
[TBL] [Abstract][Full Text] [Related]
29. Remission of eczema and recovery of Th1 polarization following treatment with Dupilumab in STAT3 hyper IgE syndrome.
Matucci-Cerinic C; Viglizzo G; Pastorino C; Corcione A; Prigione I; Bocca P; Bustaffa M; Cecconi M; Gattorno M; Volpi S
Pediatr Allergy Immunol; 2022 Apr; 33(4):e13770. PubMed ID: 35470938
[No Abstract] [Full Text] [Related]
30. Successful use of dupilumab to treat eczema in a child with X-linked agammaglobulinemia.
Atwal S; Ong PY
Ann Allergy Asthma Immunol; 2022 Sep; 129(3):384-386. PubMed ID: 35772636
[No Abstract] [Full Text] [Related]
31. Dupilumab treatment of eczema in a child with STAT3 hyper-immunoglobulin E syndrome.
Wang HJ; Yang TT; Lan CE
J Eur Acad Dermatol Venereol; 2022 May; 36(5):e367-e369. PubMed ID: 34927771
[No Abstract] [Full Text] [Related]
32. DECISA Project (DErmatology Clinics in Italy: Survey on Alitretinoin): A real-life retrospective cohort multicenter study on 438 subjects with chronic hand eczema.
Ferrucci S; Persichini P; Gola M; Scandagli I; Pigatto P; Legori A; Musumeci ML; Micali G; D'Agata E; Schena D; Azzolini A; Gallo R; Trave I; Cristaudo A; Patruno C; Napolitano M; Zucca M; Piras V; Stingeni L; Bianchi L; Corazza M; Zedde P; Foti C; Romita P; Cannavò SP; Guarneri F
Dermatol Ther; 2021 May; 34(3):e14911. PubMed ID: 33619833
[TBL] [Abstract][Full Text] [Related]
33. [Off-label use of alitretinoin].
Fritz K; Tiplica GS; Salavastru C; Onder M
Hautarzt; 2013 Oct; 64(10):748-51. PubMed ID: 24150823
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of oral alitretinoin in patients with severe chronic hand eczema--a long-term analysis from a Swiss perspective.
Blank PR; Blank AA; Szucs TD
BMC Dermatol; 2010 Jun; 10():4. PubMed ID: 20579358
[TBL] [Abstract][Full Text] [Related]
35. A review of dupilumab in the treatment of atopic diseases.
Thibodeaux Q; Smith MP; Ly K; Beck K; Liao W; Bhutani T
Hum Vaccin Immunother; 2019; 15(9):2129-2139. PubMed ID: 30785362
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy-induced eczema treated with dupilumab.
D'Erme AM; Fidanzi C; Mori N; Musettini G; Cupini S; Barbara C; Allegrini G; Bagnoni G; Janowska A
J Eur Acad Dermatol Venereol; 2024 May; 38(5):e447-e449. PubMed ID: 38084780
[No Abstract] [Full Text] [Related]
37. Alitretinoin for the treatment of severe chronic eczema of the hands.
Napolitano M; Potestio L; De Lucia M; Nocerino M; Fabbrocini G; Patruno C
Expert Opin Pharmacother; 2022 Feb; 23(2):159-167. PubMed ID: 34789049
[TBL] [Abstract][Full Text] [Related]
38. Use of alitretinoin in moderate to severe chronic hand eczema: A real-world experience in Korea.
Kim HJ; Lee SK; Baek J; Roh JY
Dermatol Ther; 2019 Jul; 32(4):e12980. PubMed ID: 31168895
[No Abstract] [Full Text] [Related]
39. Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND).
Shi VY; Bhutani T; Fonacier L; Deleuran M; Shumack S; Valdez H; Zhang F; Chan GL; Cameron MC; Yin NC
J Am Acad Dermatol; 2022 Aug; 87(2):351-358. PubMed ID: 35439608
[TBL] [Abstract][Full Text] [Related]
40. Dupilumab: A Review of Present Indications and Off-Label Uses.
Muñoz-Bellido FJ; Moreno E; Dávila I
J Investig Allergol Clin Immunol; 2022 Apr; 32(2):97-115. PubMed ID: 33661102
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
